Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about organizing hair regrowth results using a standard format in a single post for easier access. Treatments mentioned include oral minoxidil, oral finasteride, and dermarolling.

The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.

The user has been taking 1 mg of finasteride daily for four months and is questioning if they are experiencing hair regrowth, as suggested by their barber. Another user suggests taking better photos to assess the crown area more clearly.

Testing the effectiveness of Verteporfin as a potential treatment for hair loss, with users discussing their thoughts on its long-term results. Treatments mentioned include Minoxidil, Finasteride, and RU58841.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

Treatments for hair loss, including topical dutasteride minoxidil, tretonin, dermarolling, serioxyl, and redensyl over a period of 3 months; switching from RU58841 to pyrilutamide was suggested with potentially less risk of systemic side effects; and encouragement to not give up hope.

Hair loss recovery using estrogen and anti-androgen treatment for 18 months showed significant improvement. However, results vary and alternative treatments like RU58841 and Dutasteride may work without systemic feminization.

The user experienced prolonged hair shedding after restarting oral minoxidil (OM) at 2.5 mg in September 2023, following a break due to hypertrichosis. Despite seeing regrowth, the shedding has not decreased after 11 weeks on the increased dosage.

The user regrets stopping finasteride and minoxidil due to increased hair loss. They have resumed these treatments and are considering a hair transplant.

RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safety profiles.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

Rapamycin, finasteride, and minoxidil are discussed as a strategy for hair loss prevention and reversal. Pulsed dosing of rapamycin is suggested to avoid conflicting effects with minoxidil.

A 22-year-old experienced significant hair loss due to high stress, SSRI side effects, and Androgenic Alopecia, and has seen some regrowth after starting finasteride and using ketoconazole shampoo. They are inquiring if continued use of finasteride and stress reduction alone can lead to further hair regrowth.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

Long-term finasteride users often experience periodic hair shedding due to natural hair cycles, even after several years of use. Some consider switching to dutasteride, but concerns about side effects and the effectiveness of finasteride remain common.

The user is experiencing significant hair loss after switching from finasteride to dutasteride for five months. Suggestions include that the hair loss might be a normal shedding phase, with some recommending continuing the treatment for up to 24 months or considering alternatives like RU58841.

People who had posted about using pyrilutamide for hair loss, but did not return with an update; the potential side effects of pyrilutamide, RU58841 and other treatments such as minoxidil and finasteride were discussed.

A 39-year-old user experienced hair regrowth using oral dutasteride, oral minoxidil, dermastamping, and Nizoral shampoo after switching from finasteride and topical minoxidil. They are hopeful for significant improvement in their receding hairline.

Some people have seen hair regrowth on their hairline using tretinoin and minoxidil. Specific treatments discussed include tretinoin and minoxidil.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

A 34-year-old male shares his hair regrowth journey using Minoxidil Max Dual Gen with topical finasteride, hair oil, derma rolling, and nizoral shampoo, emphasizing persistence and consistency. Despite some skepticism about lighting and treatment effectiveness, he reports significant progress over 12 months.

The user is using finasteride and topical minoxidil for hair loss after previously trying them separately without success. They are experiencing a shedding phase but are committed to the treatment.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Users discuss waiting for new hair loss treatments and share struggles with side effects from current options like Minoxidil and Finasteride. They express hope for Pyrilutamide and CosmeRNA to provide better solutions.

Maintaining good hair density is more important than preventing a receding hairline, as it can enhance a mature look. Treatments discussed include finasteride, minoxidil, dutasteride, and RU58841.